ClinicalTrials.gg

Program

TQH2929

A development code. Also written as “TQH2929 Injections”, “TQH2929 Injection” and “TQH2929 injection”.

In Sino Biopharmaceutical's pipeline, IL-36R抑制剂. Its studies are mostly in Psoriasis, led by Sino Biopharmaceutical.

Furthest: phase 2, since Dec 15, 20253 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical31 open or runningphase 2since Dec 15, 2025Nov 27, 2023none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQH2929, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 27, 2023First study: phase 1 study in PsoriasisFirst studyNCT06156280 · 40 enrolled · China
  2. May 23, 2024Phase 1 study in PsoriasisNCT06433531 · 9 enrolled · China
  3. Dec 15, 2025Phase 2 study in PsoriasisPhase 2 reachedNCT07314060 · 36 enrolled · China

TargetBeta

“IL-36R抑制剂”the company's pipeline, read by Claude · source

Other programs on IL36R

ProgramCompanyFurthest phaseStudies
SHR-1139Jiangsu HengRui Medicinephase 28

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07314060Psoriasis · China2TerminatedJul 30, 202636
NCT06433531Psoriasis · China1Active, not recruitingJul 8, 20259
NCT06156280Psoriasis · China1CompletedAug 2, 202440

How it is read

Names in the registry

  • “TQH2929 Injections”, 1 entry
  • “TQH2929 Injection”, 1 entry
  • “TQH2929 injection”, 1 entry

Codes read as this program: TQH2929.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.